https://www.alphaview.kr 실시간 미국 주식 뉴스를 AI로 분석하여 시장 정보를 제공합니다. ko Mon, 26 Oct 2026 14:48:25 GMT https://www.alphaview.kr/images/brand/logo.png https://www.alphaview.kr Copyright 2026 AlphaView. All rights reserved. contact@alphaview.kr (AlphaView) contact@alphaview.kr (AlphaView) 30 https://www.alphaview.kr/news/79510-레이크우드-아메덱스-바이오테라퓨틱스-idweek-2026에서-nu-3의-광범위-항균-활성-및-낮은-내성-가능성-데이터-발표 Wed, 21 Oct 2026 12:02:00 GMT https://www.alphaview.kr/news/79510-레이크우드-아메덱스-바이오테라퓨틱스-idweek-2026에서-nu-3의-광범위-항균-활성-및-낮은-내성-가능성-데이터-발표 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/44391-lakewood-amedex-biotherapeutics-차기-nu-3-gel-2a상-임상-용량-선정-뒷받침하는-전임상-안전성-데이터-발표 Wed, 15 Jul 2026 12:04:36 GMT https://www.alphaview.kr/news/44391-lakewood-amedex-biotherapeutics-차기-nu-3-gel-2a상-임상-용량-선정-뒷받침하는-전임상-안전성-데이터-발표 기타 prnewswire PR Newswire https://www.alphaview.kr/news/43776-lakewood-amedex-biotherapeutics-pasteur-법안-재도입-지지-및-항균제-내성-퇴치-집중 Tue, 07 Jul 2026 12:04:49 GMT https://www.alphaview.kr/news/43776-lakewood-amedex-biotherapeutics-pasteur-법안-재도입-지지-및-항균제-내성-퇴치-집중 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/42972-lakewood-amedex-biotherapeutics-세계적으로-유명한-전문가-david-g-armstrong-박사를-nu-3의-2상-임상시 Thu, 25 Jun 2026 12:03:25 GMT https://www.alphaview.kr/news/42972-lakewood-amedex-biotherapeutics-세계적으로-유명한-전문가-david-g-armstrong-박사를-nu-3의-2상-임상시 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/42597-lakewood-amedex-biotherapeutics-고위험-감염병-치료용-신규-bisphosphocin-화합물-보호-물질-특허-확보 Mon, 22 Jun 2026 12:02:50 GMT https://www.alphaview.kr/news/42597-lakewood-amedex-biotherapeutics-고위험-감염병-치료용-신규-bisphosphocin-화합물-보호-물질-특허-확보 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/40632-lakewood-amedex-리드-후보-nu-3의-글로벌-ip-포트폴리오-확장-감염성-당뇨병성-족부-궤양-치료-목표 Wed, 27 May 2026 12:02:43 GMT https://www.alphaview.kr/news/40632-lakewood-amedex-리드-후보-nu-3의-글로벌-ip-포트폴리오-확장-감염성-당뇨병성-족부-궤양-치료-목표 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/37628-lakewood-amedex-biotherapeutics-nu-3-임상-2상-시험-cro로-peri와-계약-체결-발표 Tue, 12 May 2026 13:02:00 GMT https://www.alphaview.kr/news/37628-lakewood-amedex-biotherapeutics-nu-3-임상-2상-시험-cro로-peri와-계약-체결-발표 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/33427-lakewood-amedex-biotherapeutics-당뇨병성-족부-궤양-치료를-위한-선도-후보물질의-항균-저항성-관련-긍정적-데이터-발표 Fri, 01 May 2026 12:02:45 GMT https://www.alphaview.kr/news/33427-lakewood-amedex-biotherapeutics-당뇨병성-족부-궤양-치료를-위한-선도-후보물질의-항균-저항성-관련-긍정적-데이터-발표 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/32175-lakewood-amedex-biotherapeutics-이사회-멤버로-joseph-tucker-박사-임명 Tue, 28 Apr 2026 11:34:13 GMT https://www.alphaview.kr/news/32175-lakewood-amedex-biotherapeutics-이사회-멤버로-joseph-tucker-박사-임명 바이오/헬스케어 prnewswire PR Newswire https://www.alphaview.kr/news/31076-lakewood-amedex-biotherapeutics-나스닥-직상장-발표-티커-labt로-거래-개시 Thu, 23 Apr 2026 14:44:06 GMT https://www.alphaview.kr/news/31076-lakewood-amedex-biotherapeutics-나스닥-직상장-발표-티커-labt로-거래-개시 바이오/헬스케어 prnewswire PR Newswire